Can a new injection tame chronic hepatitis b?

NCT ID NCT07741461

Not yet recruiting Disease control Sponsor: Xiamen Amoytop Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This early-stage trial is evaluating an investigational drug called ACT201, given as an injection, to see if it is safe and tolerable. The study first tests single and multiple doses in healthy volunteers, then moves to people with chronic hepatitis B whose virus is already suppressed by standard therapy. The goal is to gather initial information on safety, how the drug moves through the body, and any early signs that it might help control the infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ACT201 injection
What this could lead to: If successful, this could lead to a new treatment option for chronic hepatitis B, potentially helping to control the infection and reduce liver damage.
What could go wrong: This is an early-stage trial, so the drug may not be safe or effective. Side effects are possible, and results in a small group may not apply to a larger population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPAITITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPAITITIS B

Contacts and locations

Locations

Huashan Hospital, Fudan University

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.